Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Evidence for persistence of the SHIV reservoir early after MHC haploidentical hematopoietic stem cell transplantation.

Colonna L, Peterson CW, Schell JB, Carlson JM, Tkachev V, Brown M, Yu A, Reddy S, Obenza WM, Nelson V, Polacino PS, Mack H, Hu SL, Zeleski K, Hoffman M, Olvera J, Furlan SN, Zheng H, Taraseviciute A, Hunt DJ, Betz K, Lane JF, Vogel K, Hotchkiss CE, Moats C, Baldessari A, Murnane RD, English C, Astley CA, Wangari S, Agricola B, Ahrens J, Iwayama N, May A, Stensland L, Huang MW, Jerome KR, Kiem HP, Kean LS.

Nat Commun. 2018 Oct 25;9(1):4438. doi: 10.1038/s41467-018-06736-7.

2.

Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy.

Lieberman NAP, DeGolier K, Kovar HM, Davis A, Hoglund V, Stevens J, Winter C, Deutsch G, Furlan SN, Vitanza NA, Leary SES, Crane CA.

Neuro Oncol. 2019 Jan 1;21(1):83-94. doi: 10.1093/neuonc/noy145.

PMID:
30169876
3.

CD28 blockade controls T cell activation to prevent graft-versus-host disease in primates.

Watkins BK, Tkachev V, Furlan SN, Hunt DJ, Betz K, Yu A, Brown M, Poirier N, Zheng HB, Taraseviciute A, Colonna L, Mary C, Blancho G, Soulillou JP, Panoskaltsis-Mortari A, Sharma P, Garcia A, Strobert E, Hamby K, Garrett A, Deane T, Blazar BR, Vanhove B, Kean LS.

J Clin Invest. 2018 Aug 31;128(9):3991-4007. doi: 10.1172/JCI98793. Epub 2018 Aug 13.

4.

Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice.

Pennell CA, Barnum JL, McDonald-Hyman CS, Panoskaltsis-Mortari A, Riddle MJ, Xiong Z, Loschi M, Thangavelu G, Campbell HM, Storlie MD, Refaeli Y, Furlan SN, Jensen MC, Kean LS, Miller JS, Tolar J, Osborn MJ, Blazar BR.

Mol Ther. 2018 Jun 6;26(6):1423-1434. doi: 10.1016/j.ymthe.2018.04.006. Epub 2018 Apr 7.

5.

Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates.

Taraseviciute A, Tkachev V, Ponce R, Turtle CJ, Snyder JM, Liggitt HD, Myerson D, Gonzalez-Cuyar L, Baldessari A, English C, Yu A, Zheng H, Furlan SN, Hunt DJ, Hoglund V, Finney O, Brakke H, Blazar BR, Berger C, Riddell SR, Gardner R, Kean LS, Jensen MC.

Cancer Discov. 2018 Jun;8(6):750-763. doi: 10.1158/2159-8290.CD-17-1368. Epub 2018 Mar 21.

6.

Combined OX40L and mTOR blockade controls effector T cell activation while preserving Treg reconstitution after transplant.

Tkachev V, Furlan SN, Watkins B, Hunt DJ, Zheng HB, Panoskaltsis-Mortari A, Betz K, Brown M, Schell JB, Zeleski K, Yu A, Kirby I, Cooley S, Miller JS, Blazar BR, Casson D, Bland-Ward P, Kean LS.

Sci Transl Med. 2017 Sep 20;9(408). pii: eaan3085. doi: 10.1126/scitranslmed.aan3085.

7.

Comprehensive single-cell transcriptional profiling of a multicellular organism.

Cao J, Packer JS, Ramani V, Cusanovich DA, Huynh C, Daza R, Qiu X, Lee C, Furlan SN, Steemers FJ, Adey A, Waterston RH, Trapnell C, Shendure J.

Science. 2017 Aug 18;357(6352):661-667. doi: 10.1126/science.aam8940.

8.

Systems analysis uncovers inflammatory Th/Tc17-driven modules during acute GVHD in monkey and human T cells.

Furlan SN, Watkins B, Tkachev V, Cooley S, Panoskaltsis-Mortari A, Betz K, Brown M, Hunt DJ, Schell JB, Zeleski K, Yu A, Giver CR, Waller EK, Miller JS, Blazar BR, Kean LS.

Blood. 2016 Nov 24;128(21):2568-2579. Epub 2016 Oct 6.

9.

Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality.

Saha A, O'Connor RS, Thangavelu G, Lovitch SB, Dandamudi DB, Wilson CB, Vincent BG, Tkachev V, Pawlicki JM, Furlan SN, Kean LS, Aoyama K, Taylor PA, Panoskaltsis-Mortari A, Foncea R, Ranganathan P, Devine SM, Burrill JS, Guo L, Sacristan C, Snyder NW, Blair IA, Milone MC, Dustin ML, Riley JL, Bernlohr DA, Murphy WJ, Fife BT, Munn DH, Miller JS, Serody JS, Freeman GJ, Sharpe AH, Turka LA, Blazar BR.

J Clin Invest. 2016 Jul 1;126(7):2642-60. doi: 10.1172/JCI85796. Epub 2016 Jun 13.

10.

Transcriptome analysis of GVHD reveals aurora kinase A as a targetable pathway for disease prevention.

Furlan SN, Watkins B, Tkachev V, Flynn R, Cooley S, Ramakrishnan S, Singh K, Giver C, Hamby K, Stempora L, Garrett A, Chen J, Betz KM, Ziegler CG, Tharp GK, Bosinger SE, Promislow DE, Miller JS, Waller EK, Blazar BR, Kean LS.

Sci Transl Med. 2015 Nov 25;7(315):315ra191. doi: 10.1126/scitranslmed.aad3231.

11.

Enhancement of anti-tumor CD8 immunity by IgG1-mediated targeting of Fc receptors.

Furlan SN, Mandraju R, Brewer T, Roybal K, Troutman TD, Hu W, Palm NW, Unni A, Pasare C.

MAbs. 2014 Jan-Feb;6(1):108-18.

12.

CD8 T cell effector maturation in HIV-1-infected children.

Jordan KA, Furlan SN, Gonzalez VD, Karlsson AC, Quigley MF, Deeks SG, Rosenberg MG, Nixon DF, Sandberg JK.

Virology. 2006 Mar 30;347(1):117-26. Epub 2006 Jan 6.

13.

Changes in CD4+ T-cell differentiation phenotype during structured treatment interruption in patients with chronic HIV-1 infection.

Alexander TH, Ortiz GM, Wellons MF, Allen A, Grace EJ 2nd, Schweighardt B, Brancato J, Sandberg JK, Furlan SN, Miralles GD, Nixon DF, Bartlett JA.

J Acquir Immune Defic Syndr. 2003 Dec 15;34(5):475-81.

PMID:
14657757
14.

HIV-specific CD8+ T cell function in children with vertically acquired HIV-1 infection is critically influenced by age and the state of the CD4+ T cell compartment.

Sandberg JK, Fast NM, Jordan KA, Furlan SN, Barbour JD, Fennelly G, Dobroszycki J, Spiegel HM, Wiznia A, Rosenberg MG, Nixon DF.

J Immunol. 2003 Apr 15;170(8):4403-10.

15.

A novel technique for the fluorometric assessment of T lymphocyte antigen specific lysis.

Sheehy ME, McDermott AB, Furlan SN, Klenerman P, Nixon DF.

J Immunol Methods. 2001 Mar 1;249(1-2):99-110. Erratum in: J Immunol Methods 2001 Jun 1;252(1-2):219-20.

PMID:
11226468

Supplemental Content

Loading ...
Support Center